← Human Trials & Peer-Reviewed Studies
Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism
Plain-language guide to PMID 15980949 (2005): clinical trial study of Parathyroid Hormone (PTH 1-84), hyperparathyroidism.
Key Facts
- PMID
- 15980949
- Journal
- Clinical and experimental nephrology
- Year
- 2005
- Study type
- Clinical Trial
- Authors
- Oyama Y et al. (10 authors)
- DOI
- 10.1007/s10157-005-0342-2
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a clinical trial.
The treatment strategy for secondary hyperparathyroidism is generally determined empirically with regards to present parathyroid function and serum calcium (Ca) and inorganic phosphate (Pi) levels.
More evidence is needed to avoid the aimless continuation of active vitamin D therapy.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
Nondiabetic dialysis patients whose plasma intact parathyroid hormone (iPTH) levels were greater than 300 pg/ml were included in the study.
The patients whose plasma iPTH levels were below 300 pg/ml within 48 weeks were defined as those who had been successfully treated.
How the Study Was Run
The timeline in the abstract includes 48 weeks.
Maxacalcitol was intravenously injected three times a week.
What Was Measured
The treatment strategy for secondary hyperparathyroidism is generally determined empirically with regards to present parathyroid function and serum calcium (Ca) and inorganic phosphate (Pi) levels.
PubMed files the paper under topics including Antineoplastic Agents, Calcitriol, Calcium, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Parathyroid Hormone and Phosphates.
What This Means in Plain Language
This is a clinical trial of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism over 48 weeks.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (Clinical and experimental nephrology), a journal based in Japan.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.